Significant Relation of Tissue Inhibitor of Matrix Metalloproteinase-2 and Its Combination With Matrix Metalloproteinase-2 to Survival of Patients With Cancer of Uterine Cervix
Restricted accessResearch articleFirst published online August, 2011
Significant Relation of Tissue Inhibitor of Matrix Metalloproteinase-2 and Its Combination With Matrix Metalloproteinase-2 to Survival of Patients With Cancer of Uterine Cervix
Tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) has high affinity for matrix metalloproteinase-2 (MMP-2). Few studies simultaneously investigate their implication in prognosis of patients with cervical cancer. We used reverse transcription-polymerase chain reaction and immunohistochemical method for cervical tissues and microarrays to investigate the association among TIMP-2, MMP-2, clinicopathological parameters, and prognosis of patients with cancer. Our results showed that cancer tissues exhibited less TIMP-2 expression and patients with pelvic lymph node metastasis had less TIMP-2 expression. Positive TIMP-2 constellated with negative MMP-2 indicated lower recurrence probability and better overall survival. The protective effect of TIMP-2 expression may overcome the adverse effect of MMP-2 expression in terms of disease-free interval and overall survival while neither TIMP-2 nor MMP-2 alone can be used to predict outcome. We suggest that following patients other than those with positive TIMP-2 and negative MMP-2 expression more closely and intensely may improve their prognosis.
DochertyAJPMurphyG. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Annll Rheum Dis. 1990;49:469–479.
2.
Stetler-StevensonWGBrownPDOnistoMLevyATLiottaLA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem. 1990;265(23):13933–13938.
3.
GoetzlEJBandaMJLeppertD. Matrix metalloproteinases in immunity. J Immunol. 1996;156(1):1–4.
4.
GarzettiGGCiavattiniALucariniGGoteriGDe NictolisMBiaginiG. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol. 1996;61(2):197–203.
5.
EgebladMWerbZ. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–174.
6.
ChambersAFMatrisianLM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89(17):1260–1270.
7.
LiottaLAKohnEC. The microenvironment of the tumour-host interface. Nature. 2001;411(6835):375–379.
8.
VisseRNagaseH. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839.
9.
TokurakuMSatoHMurakamiSOkadaYWatanabeYSeikiM. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT1-MMP) and with lymph node metastasis. Int J Cancer. 1995;64(5):355–359.
10.
SternlichtMDBissellMJWerbZ. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 2000;19(8):1102–1113.
11.
LohiJWilsonCLRobyJDParksWC. Epilysin: a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001;276(13):10134–10144.
12.
ToiMIshigakiSTominagaT. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat. 1998;52(1-3):113–124.
13.
EdwardsDR. The tissue inhibitors of metalloproteinases (TIMPs). In: ClendeninnNJAppeltKMatrix Metalloproteinase Inhibitors in Cancer Therapy. Totowa, NJ: Humana; 2001:67–84.
14.
BrewKDinakarpandianDNagaseHTissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477(1-2):267–283.
15.
BakerAHAhonenMKähäriV-M. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol. 2000;465:469–483.
16.
GomezDEAlonsoDFYoshijiHThorgeirssonUP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74(2):111–122.
17.
MurphyANUnsworthEJStetler-StevensonWG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993;157(2):351–358.
18.
LiHLindenmeyerFGrenetC. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastases, and prolongs survival in mice. Hum Gene Ther. 2001;12(5):515–526.
19.
WangPHKoJLTsaiHT. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array. Gynecol Oncol. 2008;108(3):533–542.
20.
OlaussenKADunantAFouretP. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–991.
21.
Al-HaddadSZhangZLeygueE. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol. 1999; 155(6):2057–2066.
22.
Handra-LucaABilalHBertrandJCFouretP. Extra-cellular signalregulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol. 2003;163(3):957–967.
23.
ChangHSuJMHuangCC. Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detect Prev. 2005;29(6):562–569.
24.
FigueiraRCGomesLRNetoJSSilvaFCSilvaIDSogayarMC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 2009;9:20–30.
25.
RemacleAGNoëlADugganC. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer. 1998;77(6):926–931.
26.
CampoETavassoliFACharonisASStetler-StevensonWGLiottaLAMerinoMJ. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumours of the ovary. Am J Pathol. 1992;6(5):500–507.
27.
DuffyMJMaguireTMHillAMcDermottEO’HigginsN. Metalloproteinases: role in breast carcinogenesis, invasion and metastases. Breast Cancer Res. 2000;2(4):252–257.
28.
VoloshenyukTGGardnerJD. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am J Physiol Regul Integr Comp Physiol. 2010;299(2):R683–R693.
29.
LewandowskiKCKomorowskiJMikhalidisDP. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab. 2006;91(8):3123–3130.
30.
RingPJohanssonKHöyhtyäMRubinKLindmarkG. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br J Cancer. 1997;76(6):805–811.
31.
CurranSDundasSRBuxtonJLeemanMFRamsayRMurrayGI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10(24):8229–8234.
32.
PengLXingXLiW. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin β1-ERK1/2 and-MMP2 signaling. Mol Cancer. 2009;8:110–122.
33.
SakataKShigemasaKNagaiNOhamaK. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17(4):673–681.
34.
SheuBCLienHCHoHN. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 2003;63(19):6537–6542.
35.
TrudelDFradetYMeyerFHarelFTêtuB. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol. 2008;39(5):731–739.
36.
RiggASLemoineNR. Adenoviral delivery of TIMP1 or TIMP2 can modify the behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Therapy. 2001;8(11):869–878.
